Skip to content
value.today

Eikon Therapeutics, Inc.

🇺🇸 Hayward, California, USABiotechnologyFounded 2019
Total raised
$1.1 B
4 rounds on record
Latest round
$351 M
Feb 2025
First round on record
May 2021
Today
Went public
See the company page

Eikon Therapeutics, Inc. is listed today as Eikon Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Eikon Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2025$351 MNo. 4$250 million to $1 billion

Eikon Therapeutics, Inc.: Raise no. 4, Feb 2025

Investors in this round

27 investors had bought by the notice of Feb 28, 2025: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Eikon Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$351 M of $400 M offered; $49 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Roger M. Perlmutter · Executive Officer, Director
  • Dror M. Berman · Director
  • James M. Tananbaum · Director
  • Joshua M. Wolfe · Director
  • Kenneth M. Frazier · Director
  • Leon M. Chen · Director
  • Robbie M. Huffines · Director
  • Robin M. Washington · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Roger M. Perlmutter, Ceo. Source: SEC Form D, newest notice filed Feb 28, 2025. Read the notice at the SEC.

equity, optionsSEC
May 2023$141 MNo. 3$50 to $250 million

Eikon Therapeutics, Inc.: Raise no. 3, May 2023

Investors in this round

21 investors had bought by the notice of Jun 1, 2023: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Eikon Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$141 M of $535 M offered; $394 M still to sell
Smallest investment taken
$33,667
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alfred M. Bowie · Executive Officer
  • Ashish M. Kheterpal · Executive Officer
  • Barbara M. Howes · Executive Officer
  • Benjamin M. Thorner · Executive Officer
  • Dan M. Anderson · Executive Officer
  • Roger M. Perlmutter · Executive Officer, Director
  • Roy M. Banes · Executive Officer
  • Russ M. Berman · Executive Officer
  • Dror M. Berman · Director
  • James M. Tananbaum · Director
  • Josh M. Wolfe · Director
  • Kenneth M. Frazier · Director
  • Leon M. Chen · Director
  • Robin M. Washington · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Roger M. Perlmutter, Ceo. Source: SEC Form D, newest notice filed Jun 1, 2023. Read the notice at the SEC.

equitySEC
Dec 2021$518 MNo. 2$250 million to $1 billion

Eikon Therapeutics, Inc.: Raise no. 2, Dec 2021

Investors in this round

43 investors had bought by the notice of Jan 6, 2022: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Eikon Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$518 M of $525 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alfred M. Bowie · Executive Officer
  • Benjamin M. Thorner · Executive Officer
  • Roger M. Perlmutter · Executive Officer, Director
  • Adam M. Goulburn · Director
  • Dror M. Berman · Director
  • James M. Tananbaum · Director
  • Leon M. Chen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Roger M. Perlmutter, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 6, 2022. Read the notice at the SEC.

equitySEC
May 2021$103 MNo. 1$50 to $250 million

Eikon Therapeutics, Inc.: Raise no. 1, May 2021

Investors in this round

12 investors had bought by the notice of May 13, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Eikon Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$103 M of $108 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Leon Chen · Executive Officer, Director
  • Roger M Perlmutter · Executive Officer, Director
  • Adam Goulburn · Director
  • Dror Berman · Director
  • James M Tananbaum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill Fishbein, Secretary. Source: SEC Form D, newest notice filed May 13, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Eikon Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2025).

    SEC Form D · Feb 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2025

That is all the official record says: Eikon Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Eikon Therapeutics, Inc. are on record.

Investors#

17 named in official filings. Open an investor to see everything it has backed.

Investors in Eikon Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Column Group IV-A, LPFund or asset managernot statednot statedHeld Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Column Group IV GP, LPFund or asset managernot statednot statedHeld Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Column Group Opportunity III GP, LPFund or asset managernot statednot statedHeld Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Column Group Opportunity III, LPFund or asset managernot statednot statedHeld Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Foresite Capital Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Foresite Capital Fund V, L.P.Fund or asset managernot statednot statedHeld Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Foresite Capital Management IV, LLCFund or asset managernot statednot statedHeld Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Foresite Capital Management V, LLCFund or asset managernot statednot statedHeld Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Foresite Capital Opportunity Fund V, L.P.Fund or asset managernot statednot statedHeld Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Foresite Capital Opportunity Management V, LLCFund or asset managernot statednot statedHeld Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Foresite Capital VI-A, LLCFund or asset managernot statednot statedHeld Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Foresite Capital VI-A Management, LLCFund or asset managernot statednot statedHeld Series A, A-1, B-1, C, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Lux Co-Invest Opportunities II, L.P.Fund or asset managernot statednot statedHeld Series A, A-1, B, B-1, C, C-1 and D preferred (Form 3, 2026)SEC Form 3
Lux Total Opportunities, L.P.Fund or asset managernot statednot statedHeld Series A, A-1, B, B-1, C, C-1 and D preferred (Form 3, 2026)SEC Form 3
Lux Venture Partners V, LLCVenture capitalnot statednot statedHeld Series A, A-1, B, B-1, C, C-1 and D preferred (Form 3, 2026)SEC Form 3
Lux Ventures V, L.P.Venture capitalnot statednot statedHeld Series A, A-1, B, B-1, C, C-1 and D preferred (Form 3, 2026)SEC Form 3
TCG Opportunity III GP, LLCOthernot statednot statedHeld Series A, A-1, C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 43 investors.

Largest shareholders today

Institutions holding Eikon Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Eikon Therapeutics, Inc.
NameRoleNamed in
Roger M. PerlmutterExecutive officerFeb 2025
Alfred M. BowieExecutive officerJun 2023
Ashish M. KheterpalExecutive officerJun 2023
Barbara M. HowesExecutive officerJun 2023
Benjamin M. ThornerExecutive officerJun 2023
Dan M. AndersonExecutive officerJun 2023
Roy M. BanesExecutive officerJun 2023
Russ M. BermanExecutive officerJun 2023
Leon ChenExecutive officerMay 2021
Roger M PerlmutterExecutive officerMay 2021
Dror M. BermanDirectorFeb 2025
James M. TananbaumDirectorFeb 2025
Joshua M. WolfeDirectorFeb 2025
Kenneth M. FrazierDirectorFeb 2025
Leon M. ChenDirectorFeb 2025
Robbie M. HuffinesDirectorFeb 2025
Robin M. WashingtonDirectorFeb 2025
Roger M. PerlmutterDirectorFeb 2025
Josh M. WolfeDirectorJun 2023
Adam M. GoulburnDirectorJan 2022
Adam GoulburnDirectorMay 2021
Dror BermanDirectorMay 2021
James M TananbaumDirectorMay 2021
Leon ChenDirectorMay 2021
Roger M PerlmutterDirectorMay 2021

Went public since 2026. Its SEC number is that of a company listed on a stock exchange.